Valneva Half-Year 2026 Financial Report
Filed with Euronext · · 41 pages · English
GENERAL INTRODUCTORY COMMENTS AND DISCLAIMER 3 I. MANAGEMENT REPORT 4 1 Overview 4 2 Operational Review 5 3 Financial Review 10 4 Operational and Strategic Outlook 2026 13 5 Risk Factors 14 6 Related Parties’ Transactions 16 II. STATUTORY AUDITORS’ REVIEW REPORT ON THE HALF YEAR FINANCIAL INFORMATION (PERIOD FROM JANUARY 1 TO JUNE 30, 2026) 17 III. UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIA
In the deck
Story so far
Earlier from Valneva
- Declaration of shares and voting rights - Status as of July 31, 2026
- Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026
- Declaration voting rights - June 30,2026
- Valneva Announces Successful Outcome of its Annual General Meeting
- Valneva Announces Availability of Documentation for its Annual General Meeting
Later from Valneva
- Pfizer et Valneva annoncent l’acceptation pour revue par l’Agence européenne des médicaments (EMA) de la demande d’autorisation de mise sur le marché de leur candidat vaccin contre la maladie de Lyme
- Déclaration d’actions et de droits de vote - Statut au 31 août 2026
- Declaration of shares and voting rights - Status as of August 31, 2026
- Declaration of shares and voting rights - Status as of September 30, 2026
- Valneva Provides Update on IXCHIQ® in the United Kingdom
Follow Valneva into a list and get an email when it puts out news.
Follow Valneva